+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Papillomavirus Vaccine Market by Vaccine Type (9-Valent, Bivalent, Quadrivalent), End User (Clinics, Hospitals, Public Health Centers), Distribution Channel, Age Group, Gender - Global Forecast 2025-2030- Product Image
Human Papillomavirus Vaccine Market by Vaccine Type (9-Valent, Bivalent, Quadrivalent), End User (Clinics, Hospitals, Public Health Centers), Distribution Channel, Age Group, Gender - Global Forecast 2025-2030- Product Image
Sale

Human Papillomavirus Vaccine Market by Vaccine Type (9-Valent, Bivalent, Quadrivalent), End User (Clinics, Hospitals, Public Health Centers), Distribution Channel, Age Group, Gender - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4858029
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The human papillomavirus vaccine market continues to evolve rapidly, shaped by innovative developments, regulatory shifts, and expanding immunization initiatives. Senior leaders face a dynamic environment where effective strategy hinges on nuanced understanding of shifting market conditions, technological advancements, and regional variations.

Market Snapshot: Human Papillomavirus Vaccine Market

The human papillomavirus vaccine market achieved significant growth from USD 4.60 billion in 2024 to USD 4.93 billion in 2025, with expectations for continued expansion at a CAGR of 7.06% to reach USD 6.93 billion by 2030. This market’s positive trajectory reflects a combination of enhanced public health strategies, regulatory developments, and new product innovations. Momentum is supported by strategic investments, robust immunization campaigns, and broadening awareness of HPV-related disease prevention among key demographic groups. As access improves and health systems adapt, emphasis is increasingly placed on efficient supply chain management, technology integration, and the evolving competitive landscape.

Scope & Segmentation

This research analyzes market development, segmentation, and region-specific trends across core industry layers and innovation vectors.

  • Vaccine Types: Includes 9-valent, bivalent, and quadrivalent options, each offering varying degrees of strain coverage and relevance to local public health priorities.
  • End Users: Covers clinics, hospitals, and public health centers, reflecting the breadth of points where HPV vaccination programs are launched and managed.
  • Distribution Channels: Examines hospital pharmacies, online pharmacies, and retail pharmacies, each increasingly vital for ensuring timely and accessible vaccine delivery.
  • Age Groups: Focuses on 9-14 years, 15-26 years, and individuals aged 27 years and above, underscoring age-specific immunization strategies and catch-up campaign considerations.
  • Gender: Addresses both male and female populations, highlighting efforts to increase uptake rates and close historical gaps in vaccination coverage.
  • Regions: Surveys major areas including Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including major European and Gulf countries, Nigeria, South Africa, and others), and Asia-Pacific (China, India, Japan, Australia, and more), each presenting unique market entry considerations and policy drivers.
  • Leading Companies: Profiles Merck & Co., GlaxoSmithKline, Shanghai Zerun Biotech, Xiamen Innovax Biotech, Shenzhen Kangtai Biological Products, Walvax Biotechnology, Beijing Zhifei Lvzhu Biopharma, and Panacea Biotec as pivotal players shaping competition and innovation.

Key Takeaways

  • The human papillomavirus vaccine market is experiencing greater complexity in both product portfolio and go-to-market strategies, calling for deeper scenario planning.
  • Innovations such as novel adjuvants and evolving delivery platforms are reshaping the efficacy profile of next-generation vaccines and unlocking potential new indications.
  • Collaboration among public health agencies, private manufacturers, and regional governments is strengthening supply chain resilience and advancing local production initiatives.
  • Market segmentation is critical: clinics serve as early adopters, hospitals offer deployment scale, and public health centers improve reach among at-risk groups.
  • The digitalization of healthcare—including real-time analytics and patient monitoring—enables refined outreach, robust pharmacovigilance, and more effective adherence programs.
  • Awareness campaigns targeting gender parity and adolescent inclusion remain central to advancing overall vaccination rates and meeting policy goals.

Impact of Recent United States Trade Tariffs

Recent United States trade tariffs are posing new challenges to supply chain stability, particularly around raw material sourcing. Manufacturers are responding by diversifying procurement strategies, evaluating local supplier options, and collaborating more closely with regulatory bodies to ensure continuous access. These developments have prompted pricing renegotiations, the adoption of scenario planning, and closer cooperation between payers and providers to balance affordability and access.

Methodology & Data Sources

This report utilizes a mixed-methods approach, combining expert interviews with immunization officials and supply chain specialists, along with quantitative data from regulatory filings, peer-reviewed journals, and policy briefs. All primary research follows rigorous confidentiality and data integrity protocols, while scenario modeling supports analyses of regulatory and tariff-induced market changes.

Why This Report Matters

  • Facilitates decisive strategic planning by senior leaders who must navigate evolving policy, competition, and demand signals in the human papillomavirus vaccine market.
  • Provides granular segmentation intelligence to support resource allocation, market entry design, and partnership identification across global regions and verticals.
  • Supports opportunity identification in emerging vaccine technologies, including digital health-enabled outreach and partnerships that enhance competitive position.

Conclusion

Organizations operating in the HPV vaccine ecosystem must continually adjust strategies to address regulatory, technological, and process change. This research delivers a reliable foundation for critical decision-making, tailoring actionable insights to the needs of industry leadership.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of 9-valent HPV vaccines driving competition and pricing dynamics in developed markets
5.2. Expansion of national immunization programs in emerging economies boosting HPV vaccine uptake among adolescents
5.3. Ongoing research into single-dose HPV vaccine regimens aiming to improve compliance and reduce costs
5.4. Strategic partnerships between vaccine manufacturers and governments for large-scale HPV vaccination campaigns
5.5. Integration of digital health platforms to track HPV vaccination coverage and improve patient adherence
5.6. Increasing investment in next-generation HPV vaccines targeting broader strain coverage and therapeutic applications
5.7. Challenges of cold chain logistics in rural regions affecting HPV vaccine distribution and access
5.8. Growing public-private initiatives to address HPV vaccine hesitancy through targeted awareness programs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Papillomavirus Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. 9-Valent
8.3. Bivalent
8.4. Quadrivalent
9. Human Papillomavirus Vaccine Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Hospitals
9.4. Public Health Centers
10. Human Papillomavirus Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Human Papillomavirus Vaccine Market, by Age Group
11.1. Introduction
11.2. 15-26 Years
11.3. 27 Years And Above
11.4. 9-14 Years
12. Human Papillomavirus Vaccine Market, by Gender
12.1. Introduction
12.2. Female
12.3. Male
13. Americas Human Papillomavirus Vaccine Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human Papillomavirus Vaccine Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human Papillomavirus Vaccine Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Shanghai Zerun Biotech Co., Ltd.
16.3.4. Xiamen Innovax Biotech Co., Ltd.
16.3.5. Shenzhen Kangtai Biological Products Co., Ltd.
16.3.6. Walvax Biotechnology Co., Ltd.
16.3.7. Beijing Zhifei Lvzhu Biopharma Co., Ltd.
16.3.8. Panacea Biotec Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HUMAN PAPILLOMAVIRUS VACCINE MARKET: RESEARCHAI
FIGURE 26. HUMAN PAPILLOMAVIRUS VACCINE MARKET: RESEARCHSTATISTICS
FIGURE 27. HUMAN PAPILLOMAVIRUS VACCINE MARKET: RESEARCHCONTACTS
FIGURE 28. HUMAN PAPILLOMAVIRUS VACCINE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 71. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 72. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 73. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 78. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 79. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 80. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 81. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 88. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 89. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 90. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 100. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 110. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 132. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 133. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 142. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 143. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 152. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 162. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 163. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 164. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 165. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 172. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 173. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 182. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 202. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 212. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 213. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 222. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 232. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 233. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 234. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 235. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 242. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 243. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 252. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 262. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 272. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 273. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 282. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 283. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 284. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 285. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 292. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 302. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 303. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 304. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 305. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 312. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 313. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 314. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 315. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024

Samples

Loading
LOADING...

Companies Mentioned

  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Shanghai Zerun Biotech Co., Ltd.
  • Xiamen Innovax Biotech Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Zhifei Lvzhu Biopharma Co., Ltd.
  • Panacea Biotec Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.93 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.93 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 195 Pages
  • Global
From
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 130 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report - Product Image

Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From

About the HPV Vaccine Market

The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer. The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries. Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.